Beta
43405

Phase 3 study comparing weekly concomitant boost for breast cancer patients treated with conservative breast surgery with sequential boost

Article

Last updated: 04 Jan 2025

Subjects

-

Tags

Oncology and Nuclear Medicine.

Abstract

Background: Radiation therapy after breast conserving surgery is a standard part of treatment for invasive breast cancer. Based on radiobiological models, it was found that shorter hypofractiontaed radiation schedules had equivalent local control to standard radiation therapy. Radiation boost to the tumor bed was evident to be associated with significant improvement in local control.
Methods: This study included 48 female patients with early breast cancer who underwent breast conservative surgery. There were two arm of radiation, hypofractionated radiotherapy with concomitant boost (group A) - hypofractionated radiotherapy with sequential boost (group B).
Results: after median follow up 43 months range (21-57). Four year over all survival rate for concomitant boost arm was (91.67%) and sequential boost arm was (87.50%), Four year disease free survival rate for concomitant boost arm was (87.5%) and sequential boost arm was (79.17 %). late skin toxicity, grade 0 was (72.73%) in concomitant boost arm and (54.55%) in sequential boost arm and grade 1 was (9.09%) in concomitant boost arm and (31.82%) in sequential boost arm and grade 2 was (18.19) in concomitant boost arm and (13.55%) in sequential boost arm, grade 3 late lung toxicity was (4.17%) in concomitant boost arm and (12.50%) in sequential boost arm, cardiac toxicity in concomitant boost arm (8.33%) and sequential boost arm (16.67%).The ipsilateral lymphedema after 24 months of follow up G2 (4.55%) in concomitant boost arm G3 (4.55%) in in sequential boost arm.
Conclusion: A shortened whole breast irradiation schedule with a weekly concomitant boost may be an alternative option with acceptable toxicity and excellent cosmesis.

DOI

10.21608/smj.2019.43405

Authors

First Name

Mohmed

Last Name

Gaber

MiddleName

Soliman

Affiliation

Department of Clinical Oncology, Faculty of Medicine, Sohag University.

Email

mohamed_marzouk@med.sohag.edu.eg

City

Sohag

Orcid

-

First Name

Ali

Last Name

Ali

MiddleName

Mohammed

Affiliation

Department of Clincal Oncology and Nuclear Medicine, Faculty of Medicine, Sohag University.

Email

ali.mohamed.ali@med.sohag.edu.eg

City

Sohag

Orcid

-

First Name

Emad El Din

Last Name

Hassan

MiddleName

Nabil

Affiliation

Department of Clinical Oncology ,Faculty of Medicine, Sohag University.

Email

emadeldin_hassan@med.sohag.edu.eg

City

Sohag

Orcid

-

First Name

Asmaa

Last Name

Hussein

MiddleName

-

Affiliation

Department of Clincal Oncology and Nuclear Medicine, Faculty of Medicine, Sohag University.

Email

asmaahussin@med.sohag.edu.eg

City

Sohag

Orcid

-

Volume

23

Article Issue

Issue 1

Related Issue

5652

Issue Date

2019-01-01

Receive Date

2018-11-18

Publish Date

2019-01-01

Page Start

172

Page End

178

Print ISSN

1687-8353

Online ISSN

2682-4159

Link

https://smj.journals.ekb.eg/article_43405.html

Detail API

https://smj.journals.ekb.eg/service?article_code=43405

Order

28

Type

Original Article

Type Code

785

Publication Type

Journal

Publication Title

Sohag Medical Journal

Publication Link

https://smj.journals.ekb.eg/

MainTitle

Phase 3 study comparing weekly concomitant boost for breast cancer patients treated with conservative breast surgery with sequential boost

Details

Type

Article

Created At

22 Jan 2023